• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New drug applications; drug master files. Food and Drug Administration, HHS. Final rule.

出版信息

Fed Regist. 2000 Jan 12;65(8):1776-80.

PMID:11010656
Abstract

The Food and Drug Administration (FDA) is revising its regulation governing drug master files (DMF's). FDA is removing the provision for submitting Type I DMF's and will no longer permit information submitted in a Type I DMF to be incorporated by reference in investigational new drug applications (IND's), new drug applications (NDA's), abbreviated new drug applications (ANDA's), or amendments or supplements to any of these. This rule is intended to eliminate submissions of information that are not necessary either to conduct inspections of manufacturing facilities or to review the chemistry, manufacturing, and controls sections of IND's, NDA's, and abbreviated applications.

摘要

相似文献

1
New drug applications; drug master files. Food and Drug Administration, HHS. Final rule.
Fed Regist. 2000 Jan 12;65(8):1776-80.
2
Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.赛诺菲制药公司等；21项新药申请和62项简略新药申请的批准撤回——美国食品药品监督管理局。通知。
Fed Regist. 1998 May 12;63(91):26191-3.
3
Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.授权与组织；药品评价和研究中心——美国食品药品监督管理局。最终规则。
Fed Regist. 1993 Apr 1;58(61):17093-4.
4
Investigational new drug applications and new drug applications--FDA. Final rule.研究性新药申请和新药申请——美国食品药品监督管理局。最终规则。
Fed Regist. 1998 Feb 11;63(28):6854-62.
5
Investigational new drug applications; amendment to clinical hold regulations for products intended for life-threatening diseases and conditions. Food and Drug Administration, HHS. Final rule.
Fed Regist. 2000 Jun 1;65(106):34963-71.
6
Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.研究性新药申请；临床搁置；直接最终规则的配套文件——美国食品药品监督管理局。拟议规则。
Fed Regist. 1998 Dec 14;63(239):68710-2.
7
Erythrityl tetranitrate; drug efficacy study implementation; revocation of exemption; opportunity for a hearing--FDA. Notice.
Fed Regist. 1998 Jun 23;63(120):34188-90.
8
Investigational new drug applications; clinical holds--FDA. Direct final rule.研究性新药申请；临床搁置——美国食品药品监督管理局。直接最终规则。
Fed Regist. 1998 Dec 14;63(239):68676-8.
9
Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.美国食品药品监督管理局（FDA）批准一种新药上市的申请：专利提交与列名要求以及对证明药品专利无效或不会被侵权的简略新药申请批准给予30个月延缓的适用。最终规则。
Fed Regist. 2003 Jun 18;68(117):36675-712.
10
Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.新药上市批准申请；完整回复函；未批准申请的修订。最终规则。
Fed Regist. 2008 Jul 10;73(133):39588-611.